You are viewing: UK Real World Evidence Solutions Market analysis

The UK Real World Evidence Solutions Market was valued at $281.5 Million in 2025 and projected to reach to $577.8 Million by 2030, representing a compound annual growth rate of 15.5%. The UK Real World Evidence Solutions Market is poised for sustained growth through 2030, driven by NHS modernisation initiatives and increasing recognition of real-world data's value in healthcare delivery.

UK Real World Evidence Solutions Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Real World Evidence Solutions Market Trends and Insights

  • The UK market is driven by increasing adoption of real-world data in clinical decision-making, regulatory support for evidence-based healthcare, and growing investment in digital health infrastructure across the National Health Service.
  • The UK's strong regulatory framework and emphasis on post-market surveillance have positioned the country as a leader in RWE adoption within Europe. The UK market's 15.5% compound annual growth rate significantly outpaces global trends, reflecting the country's commitment to integrating real-world evidence into pharmaceutical development and healthcare policy.
  • UK healthcare providers and pharmaceutical companies are increasingly leveraging RWE to improve patient outcomes, reduce costs, and accelerate drug approvals.
  • Between 2025 and 2030, the UK market is expected to nearly double, driven by enhanced data interoperability, expanded use of electronic health records, and greater collaboration between NHS trusts and life sciences organizations..

Key Market Statistics

  • CAGR (2025-2030) 15.5% CAGR
  • Market Size, 2025 ~USD 281.5 Million
  • Forecast, 2030 ~USD 577.8 Million
  • Country UK

UK Real World Evidence Solutions Market Overview

Market Valuation Growth :

The UK Real World Evidence Solutions Market is valued at £281.5 million in 2025 and is projected to reach £577.8 million by 2030, representing a robust 15.5% CAGR over the forecast period.

NHS Digital Health Integration :

Growing investment in digital health infrastructure across the National Health Service is accelerating the adoption of real-world evidence solutions, enabling better patient outcomes and operational efficiency.

Regulatory Support & Clinical Adoption :

UK regulatory bodies increasingly support evidence-based healthcare practices, driving adoption of real-world data in clinical decision-making and pharmaceutical development processes.

Outpacing Global Growth :

The UK market CAGR of 15.5% exceeds the global average of 14.8%, positioning the UK as a high-growth market for real-world evidence solutions in Europe.

UK Real World Evidence Solutions Market Dynamics

  • Pharmaceutical companies, healthcare providers, and payers are investing heavily in RWE capabilities to support drug development, post-market surveillance, and value-based care models.
  • Regulatory frameworks continue to evolve favourably, with MHRA and NICE increasingly incorporating real-world evidence into approval and reimbursement decisions.
  • Digital health infrastructure expansion and interoperability improvements across NHS trusts will further accelerate market penetration and create new opportunities for solution providers..

Related Ecosystem

Healthcare It

Top Technologies
  • Computed Tomography (CT)
  • Machine Learning
  • Magnetic Resonance Imaging (MRI)
  • Natural Language Processing (NLP)
  • Predictive Analytics
Top Companies
  • CERNER CORPORATION
  • PHILIPS HEALTHCARE
  • Oracle Corporation
  • GE HealthCare Technologies Inc.
  • Siemens healthineers

    Key Takeaways

    • The UK Real World Evidence Solutions Market is valued at £281.5 million in 2025 and is projected to reach £577.8 million by 2030, representing a 15.5% CAGR.
    • The UK's regulatory environment and NHS infrastructure create a favorable landscape for RWE adoption and implementation across healthcare systems.
    • UK pharmaceutical and healthcare organizations are increasingly investing in real-world data capabilities to support clinical trials, post-market surveillance, and regulatory submissions.
    • The UK market growth is accelerated by digital health initiatives, interoperability standards, and collaboration between public health institutions and private life sciences companies.

    Real World Evidence Solutions Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment INTEGRATED DATA SETS (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 14.8% from 2025 to 2030
    Largest Segment CLOUD-BASED (Deployment Mode)
    Market Size Base Year (Billions) ~USD 5.43 (2025)
    Revenue Forecast (Billions) ~USD 10.83 (2030)
    Segments Covered Component, Type, Application, Therapeutic Area, Revenue Model, Deployment Mode, End User, Healthcare Payer, Healthcare Provider

    UK Real World Evidence Solutions Market Report Segmentation

    9 segment dimensions are covered across the global market.

    By Component

    • Data Sets
    • Services

    By Type

    • Cardiovascular Diseases
    • Claims Data Sets
    • Clinical Settings Data
    • Clinical Settings Data Sets
    • Clinics & Other Outpatient Settings
    • Disparate Data Sets
    • Hospitals
    • Immunology
    • Integrated Data Sets
    • Neurology
    • Oncology
    • Other Healthcare Providers
    • Other Types
    • Patient-Powered Data Sets
    • Pharmacy Data Sets
    • Private Payers
    • Public Payers
    • Rare Diseases
    • Registry-Based Data Sets

    By Application

    • Clinical & Regulatory Decision-Making
    • Clinical &Regulatory Decision-Making
    • Clinical And Regulatory Decision-Making
    • Drug Development & Approvals
    • Drug Development And Approvals
    • Market Access & Reimbursement/ Coverage Decision-Making
    • Market Access & Reimbursement/Coverage Decision Making
    • Market Access And Reimbursement/ Coverage Decision Making
    • Medical Device Development & Approvals
    • Medical Device Development And Approvals
    • Other Applications
    • Post Market Surveillance
    • Post-Market Surveillance

    By Therapeutic Area

    • Cardiovascular Diseases
    • Immunology
    • Neurology
    • Oncology
    • Other Therapeutic Areas
    • Rare Diseases

    By Revenue Model

    • License
    • Pay-Per-Usage (Value-Based Pricing)
    • Subscription

    By Deployment Mode

    • Cloud-Based
    • Hybrid
    • On-Premises

    By End User

    • Healthcare Payers
    • Healthcare Providers
    • Medtech Companies
    • Other End Users
    • Pharmaceutical & Biotechnology Companies

    By Healthcare Payer

    • Private Payers
    • Public Payers

    By Healthcare Provider

    • Clinics & Other Outpatient Settings
    • Hospitals
    • Other Healthcare Providers

    UK: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    HEALTHCARE PAYERS41.547.554.362.271.381.894108.114.8
    HEALTHCARE PROVIDERS56.965.675.787.4101.1117.1135.8157.715.8
    MEDTECH COMPANIES27.932.337.443.450.458.668.279.516.3
    OTHER END USERS13.715.717.920.423.326.730.63514.4
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES72.883.796.3110.9127.9147.6170.7197.515.5
    TOTAL212.9244.7281.5324.3374431.9499.3577.815.5

    Target Audience

    • Pharmaceutical Companies : UK-based and international pharma firms need RWE solutions to support drug development, post-market surveillance, and MHRA/NICE submissions with real-world data evidence.
    • NHS Trusts & Healthcare Providers : Hospital networks and primary care organisations require real-world evidence solutions to optimise clinical pathways, improve patient outcomes, and support digital transformation initiatives.
    • Health Technology Vendors : Digital health and EHR solution providers need market intelligence to integrate RWE capabilities and position offerings within the expanding NHS digital ecosystem.
    • Payers & Health Economics Teams : NHS commissioners, private insurers, and health economics consultants use RWE data for reimbursement decisions, health technology assessments, and value-based contracting.
    • Clinical Research Organisations : CROs and research institutions operating in the UK require market insights to develop real-world evidence services and support regulatory submissions with UK-specific data.

    Key Companies in the UK Real World Evidence Solutions Market

    CompanyHQOwnershipStrongest segments
    IQVIAUnited StatesPublic CompanyTechnology & Analytics Solutions,Research & Development Solutions,Contract Sales & Medical Solutions,
    ICON PLCIrelandPublic CompanyFull-service clinical development (Phase I–IV, peri/post-approval),Functional service partnerships & contract staffing,Laboratory, bioanalytical, biomarker, and imaging services,
    SYNEOS HEALTHUnited StatesPrivate CompanyClinical Development Services,Commercialization & Launch Services,Consulting, Advisory & Data/Software,
    PAREXEL INTERNATIONAL (MA) CORPORATIONUnited StatesPrivate CompanyClinical trial management and monitoring,Biostatistics and data management,Regulatory affairs and pharmacovigilance,
    FLATIRON HEALTHUnited StatesSubsidiaryOncology EHR and practice management software,Life sciences real-world data subscriptions and licensing,Evidence-generation partnerships and analytics services,
    FORTREAUnited StatesPublic CompanyClinical Development (Phase I–IV and RWE),Clinical Pharmacology and Early Development,Consulting, Market Access, HEOR and RWE Services,
    ORACLEUnited StatesPublic CompanyCloud SaaS (Fusion ERP/EPM/SCM/HCM, NetSuite, CX),Cloud Infrastructure & Autonomous Database,On-Premise Licenses & License Support,
    ELEVANCE HEALTHUnited StatesPublic CompanyHealth Benefits (Commercial & Specialty),Health Benefits (Government: Medicare, Medicaid, FEP),CarelonRx (Pharmacy Services),
    TRINITYUnited StatesPublic CompanyRailcar Leasing and Services Group,Rail Products Group,
    MEDIDATAUnited StatesPrivate CompanyCore EDC and clinical data management,Decentralized trial and patient engagement solutions,Advanced analytics and data-driven services,

    IQVIA

    IQVIA is a large public company headquartered in the United States with approximately 93,000 employees. The company operates in the healthcare and life sciences industry.

    ICON PLC

    Icon PLC is a public company founded in 1989 and headquartered in Ireland. With 40,350 employees, the company provides clinical research and development services globally.

    SYNEOS HEALTH

    Syneos Health is a private company founded in 2010 and based in the United States. With 28,768 employees, the company offers clinical research, consulting, and commercial services to the life sciences industry.

    PAREXEL INTERNATIONAL (MA) CORPORATION

    Parexel International (MA) Corporation is a private company founded in 1982 and headquartered in the United States. With 18,900 employees, the company provides clinical research, consulting, and regulatory services to the pharmaceutical and biotech industries.

    FLATIRON HEALTH

    FlatIron Health is a subsidiary company founded in 2012 and based in the United States. The company specializes in oncology software and data solutions for healthcare providers.

    FORTREA

    Fortrea is a public company founded in 2023 and based in the United States. With 14,000 employees, the company operates in the clinical research and contract research organization sectors.

    ORACLE

    Oracle is a large public technology company founded in 1977 and headquartered in the United States. With 141,000 employees, the company develops database software, cloud computing solutions, and enterprise applications.

    ELEVANCE HEALTH

    Elevance Health is a public company founded in 2001 and based in the United States. With 96,615 employees, the company operates as a major health insurance and managed care provider.

    TRINITY

    Trinity is a public company founded in 1933 and headquartered in the United States. With 6,110 employees, the company operates in the healthcare services sector.

    MEDIDATA

    Medidata is a private company founded in 1999 and based in the United States. With 1,998 employees, the company provides cloud-based clinical trial software and data analytics solutions for the life sciences industry.

    Reasons to Buy this Report

    • UK-Specific Market Sizing : Access precise valuation data for the UK market (£281.5M in 2025) with detailed forecasts through 2030, enabling accurate budget allocation and investment planning for UK operations.
    • NHS & Regulatory Insights : Understand how NHS modernisation, MHRA regulations, and NICE guidelines are shaping real-world evidence adoption, helping you align solutions with UK healthcare priorities.
    • Competitive Growth Intelligence : Benchmark your UK performance against market growth rates (15.5% CAGR) and identify expansion opportunities in a market outpacing global averages.
    • Stakeholder Decision Support : Equip pharmaceutical companies, healthcare providers, and payers with UK-focused data to justify RWE investments and support value-based care transformation initiatives.
    • Strategic Market Positioning : Leverage UK-specific insights on digital health infrastructure, clinical adoption trends, and regulatory support to develop targeted go-to-market strategies and partnership opportunities.

    Frequently asked questions

    What is the current size of the UK Real World Evidence Solutions Market?

    The UK Real World Evidence Solutions Market is valued at £281.5 million in 2025 and is expected to grow to £577.8 million by 2030.

    What is the growth rate of the UK Real World Evidence Solutions Market?

    The UK market is growing at a compound annual growth rate (CAGR) of 15.5% from 2025 to 2030.

    What factors are driving growth in the UK Real World Evidence Solutions Market?

    Key drivers include NHS digital transformation initiatives, regulatory support for real-world data in drug approvals, increased adoption of electronic health records, and growing collaboration between healthcare providers and pharmaceutical companies in the UK.

    How does the UK market compare to global trends?

    The UK's 15.5% CAGR outpaces the global average of 14.8%, reflecting the country's advanced healthcare infrastructure and strong regulatory framework for real-world evidence adoption.

    What role does the NHS play in the UK Real World Evidence Solutions Market?

    The NHS is a major driver of RWE adoption in the UK, leveraging real-world data to improve patient outcomes, support clinical decision-making, and enhance post-market surveillance across the healthcare system.

    RESEARCH METHODOLOGY

    The study involved five activities to estimate the current size of the real world evidence solutions market. Exhaustive secondary research was conducted to collect information on the market and its varied subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

    Secondary Research

    In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to to identify and collect information for the study of the real world evidence solutions market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends, to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various supply-side & demand-side sources were interviewed to obtain qualitative & quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, biostatisticians, and related key executives from various companies and organizations operating in the real world evidence solutions market. Primary sources from the demand side included industry experts, such as directors of pharmaceutical, biopharmaceuticals, medical device companies, contract manufacturing organizations, directors of RWE vendor companies, directors of clinical research organizations, and other related key executives.

    The following is a breakdown of the primary respondents:

    Real World Evidence Solutions Market

    Note 1: Others include sales, marketing, and product managers.

    Note 2: Tiers of companies are defined based on their total revenues. As of 2024. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the RWE solutions market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research.
    • In terms of value, the industry’s supply chain and market size have been determined through primary and secondary research processes.
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
    Real World Evidence Solutions Market

    Data Triangulation

    The market was split into several segments and subsegments after arriving at the overall market size using the market size estimation processes. To complete the overall market engineering process and arrive at the exact statistics of each market segment and sub-segment, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the RWE solutions market.

    Market Definition

    Real world evidence is the clinical evidence about the usage & potential benefits or risks of a medical product derived from real world data analysis. This evidence is derived from the analysis of real world data (RWD), information collected from sources such as electronic health records, insurance claims, patient registries, and data gathered from other sources (such as digital health technologies) that can inform individuals on health status.

    Stakeholders

    • Original Equipment Manufacturers
    • Pharmaceutical & Biotechnology Companies
    • Medical Device Companies
    • Clinical Laboratories
    • Contract Research Organizations
    • Medical Device Research & Consulting Firms
    • Academic & Research Institutes
    • Government Associations
    • Market Research & Consulting Firms
    • Venture Capitalists & Investors
    • Hospitals & Clinics
    • Insurers
    • Academic Medical Centers
    • Government Research Organizations
    • Contract & Research Organizations
    • Regulatory Agencies

    Report Objectives

    • To define, describe, and forecast the global RWE solutions market based on component, application, revenue model, deployment mode, end user, and region.
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, opportunities, and challenges)
    • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and to provide details of
      the competitive landscape for market leaders.
    • To forecast the size of the market segments with respect to five regions, namely,
      North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. (along with country-wise segments)
    • To profile the key players and comprehensively analyze their market shares and core competencies in the RWE solutions market.
    • To track & analyze competitive developments such as business expansions, partnerships, agreements, collaborations, acquisitions, and innovative product/service launches in the global RWE solutions market.

    Get the Full Real World Evidence Solutions Market Report

    Full forecast, segment splits, and company analysis for all Real World Evidence Solutions Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status